The optimal duration of immune checkpoint inhibitor therapy in melanoma brain metastases remains unclear. Discontinuation of nivolumab plus ipilimumab within 24 months after response is associated with survival outcomes comparable to continued treatment, and discontinuation after complete response—including due to toxicity—can result in durable disease control. Immune-related adverse events are associated with improved overall survival, independent of anti-tumor necrosis factor-alpha use.
Ryan Sullivan
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ryan
Contact Ryan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack